Back to top
more

Clearside Biomedical (CLSD)

(Delayed Data from NSDQ)

$0.41 USD

0.41
284,721

-0.01 (-3.37%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $0.40 -0.01 (-2.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 8.33% and 785.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 31.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 23.08% and 13.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Clearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy

by Zacks Equity Research

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 310.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 7.25% and 121.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)

by Zacks Equity Research

Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 64.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -59.02% and 2.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -21.43% and 76.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 88.10% and 28.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 10.78% and 6.95%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5.63% and 1.57%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 10.17% and 44.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.14% and 98.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of -27.40% and 119.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 74.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 26.67% and 79.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?